Inhibitor of dihydroorotate dehydrogenase (IC50
= 2.5 μ
M). Inhibits de novo
pyrimidine synthesis in human T cells in vitro
; also inhibits lymphocyte proliferation. Exhibits efficacy in several animal models of autoimmune disease, arthritis and graft rejection. Active metabolite, teriflunomide
(A77 1726, Cat. No. 5069), also available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski et al.
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.
Brazelton and Morris
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene et al.
The citations listed below are publications that use Tocris products. Selected citations for Leflunomide include:
Showing Results 1 - 1 of 1